Retrospective study of 70 cases with the head and neck non-parameningeal rhabdomyosarcoma
10.3760/cma.j.cn115330-20230712-00002
- VernacularTitle:头颈部非脑膜旁区横纹肌肉瘤70例回顾性研究
- Author:
Ge ZHANG
1
;
Shengcai WANG
;
Yan SU
;
Zhikai LIU
;
Guoxia YU
;
Jie ZHANG
;
Lin MEI
;
Nian SUN
;
Yanzhen LI
;
Xuexi ZHANG
;
Qiaoyin LIU
;
Zhiyong LIU
;
Xiaodan LI
;
Xin NI
Author Information
1. 国家儿童医学中心 首都医科大学附属北京儿童医院耳鼻咽喉头颈外科，北京 100045
- Keywords:
Rhabdomyosarcoma;
Head and neck;
Multidisciplinary;
Prognosis
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2024;59(2):133-139
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the treatment outcomes and prognoses of children with head and neck non-parameningeal rhabdomyosarcoma (HNnPM RMS).Methods:A retrospective analysis was performed on the clinical data of children with HNnPM RMS admitted to Beijing Children′s Hospital from September 2012 to September 2022. The clinical features, comprehensive treatment modes and prognoses of the patients were analyzed. The overall survival rate (OS) and event free survival rate (EFS) were calculated using the Kaplan-Meier method, and univariate analysis was performed using the Log-rank test.Results:A total of 70 children were included in this study, 38 males and 32 females, with a median age of 47 months (2-210 months). Pathological subtypes including the embryonal in 27 cases, the alveolar in 36 cases and the spindle cell and sclerosing in 7 cases. Thirty children (83.3%) with alveolar type were positive for FOXO1 gene fusion. All 70 children underwent chemotherapy, including 38 with neoadjuvant chemotherapy and 32 with adjuvant chemotherapy. Sixty of 70 children underwent surgery, of whom, 10 underwent two or more surgeries. There were 63 children underwent radiotherapy, including 54 with intensity-modulated radiation therapy, 4 with particle implantation and 5 with proton therapy. The median follow-up was 45 (5-113) months, the 5-year OS was 73.2%, and the 5-year EFS was 57.7%. Univariate analysis showed lymph node metastasis ( χ2=5.022, P=0.025), distant metastasis ( χ2=8.258, P=0.004), and high Intergroup Rhabdomyosarcoma Study (IRS) group ( χ2=9.859, P=0.029) as risk factors for poor prognosis. Before June 2016, the 5-year OS based on BCH-RMS-2006 scheme was 63.6%, and after 2016, the 5-year OS based on CCCG-RMS-2016 scheme was 79.6%. Conclusion:Multidisciplinary combined standardized treatment can offer good treatment outcome and prognosis for children with HNnPM RMS. Local control is a key to the efficacy of comprehensive treatment.
